Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Alexandra Durr on riluzole in patients with spinocerebellar ataxia type 2

    Alexandra Durr on riluzole in patients with spinocerebellar ataxia type 2

    FromThe Lancet Neurology in conversation with

    Start listeningView podcast show

    Alexandra Durr on riluzole in patients with spinocerebellar ataxia type 2

    FromThe Lancet Neurology in conversation with

    ratings:
    Length:
    8 minutes
    Released:
    Feb 22, 2022
    Format:
    Podcast episode

    Description

    Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.Read the full article:Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL)
    Released:
    Feb 22, 2022
    Format:
    Podcast episode

    Titles in the series (100)

    Our Editors and and the journal’s authors explore their research and its impact on people’s health, health care, and health policy in this regular podcast.